论文部分内容阅读
目的探讨沙利度胺对伊立替康致迟发性腹泻防治效果的影响。方法选取2012年10月至2014年12月来本院就诊接受伊立替康治疗的恶性肿瘤患者73例,将其采用随机数字表法分为两组,观察组36例患者化疗前给予沙利度胺,对照组37例患者常规预防性给药。比较两组患者的腹泻程度、腹泻发生率及不良反应情况。结果观察组患者腹泻3~4级发生率、腹泻发生率及恶心、呕吐发生例数均低于对照组,差异均有统计学意义(均P<0.05)。结论沙利度胺能有效预防伊立替康所致迟发性腹泻的发生,可降低部分不良反应发生,有利于提高患者的化疗耐受性,安全有效。
Objective To investigate the effect of thalidomide on the prevention and treatment of idiotecan-induced delayed diarrhea. Methods Totally 73 patients with malignant tumors receiving irinotecan from October 2012 to December 2014 in our hospital were divided into two groups according to the random number table. 36 patients in the observation group were given thalidomide Amine, control group, 37 patients were routinely prophylactic. The degree of diarrhea, the incidence of diarrhea and adverse reactions in both groups were compared. Results The incidence of diarrhea grade 3 to 4, the incidence of diarrhea and the incidence of nausea and vomiting in observation group were lower than those in control group (all P <0.05). Conclusion Thalidomide can effectively prevent the occurrence of delayed diarrhea caused by irinotecan, reduce the incidence of some adverse reactions, improve the tolerance of patients with chemotherapy, and be safe and effective.